focus -WSS

focus

author：fashion 2025-09-03 07:53:44 - browse：7

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Readout Newsletter: Amgen, Regeneron, BGI Group and more

WSS

Readout Newsletter: Amgen, Regeneron, BGI Group and more

An inside look at PIPEs, biotech's buzzy new financing tool

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

FogPharma raises $145 million in rare Series E round

AI gets buy

FogPharma raises $145 million in rare Series E round

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AstraZeneca stays mum on Medicare drug pricing negotiations

Novavax promises a turnaround & Lilly roils the obesity market

Problems with a popular proposal to regulate AI in health care

In age of alternative facts, a scholarly course on calling out crap

AstraZeneca stays mum on Medicare drug pricing negotiations

Continuity nursing helped my family in our darkest PICU moments

Medical device lobby: We're tired of waiting on Medicare coverage

As demand for Covid shots wanes, Moderna seeks its next success

A protest over insulin prices is seen as a fight for life

entertainment

A Q&A with Aletha Maybank, AMA’s chief health equity officer

How to fix the rural physician shortage in the U.S.

The Biogen Aduhelm mess could happen again

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

AstraZeneca loses challenge to Medicare drug price negotiation

hotspot

knowledge

leisure time

Wikipedia